Expression of p53 in upper urinary tract urothelial carcinoma

Nature Reviews Urology

Volumn 8, Issue 9, 2011, Pages 516-522

  Mitchell, Stephen ^a   Mayer, Erik ^b   Patel, Anup ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; CYCLIN E; CYCLINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY KI 67; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P27; PROTEIN P53; SURVIVIN; UVOMORULIN;

ABLATION THERAPY; CANCER SURVIVAL; DISEASE COURSE; DISEASE DURATION; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MORBIDITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; URETEROSCOPY; URINARY TRACT CARCINOMA; UTERUS BIOPSY;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 80052764847     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.92     Document Type: Review

References (46)

1. Landis, S. H., Murray, T., Bolden, S. & Wingo, P. A. Cancer statistics. CA Cancer J. Clin. 48, 6-29 (1998).
2. Mitchell S., Havranek, E. & Patel, A. First digital flexible ureterorenoscope: initial experience. J. Endourol. 22, 47-50 (2008).
3. Hall, M. C. et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52, 594-601 (1998).
4. Lane, D. P. p53, guardian of the genome. Nature 358, 15-16 (1992).
5. Smith, N. D., Rubenstein, J. N., Eggener, S. E. & Kozlowski, J. M. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J. Urol. 169, 1219-1228 (2003). (Pubitemid 36323756)
6. Boehme, K. A. & Blattner, C. Regulation of p53-insights into a complex process. Crit. Rev. Biochem. Mol. Biol. 44, 367-392 (2009).
7. Davidoff, A. M., Kerns, B. J., Iglehart, J. D. & Marks, J. R. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res. 51, 2605-2610 (1991).
8. Kaghad, M. et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819 (1997). (Pubitemid 27357971)
9. Yang, A. et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 2, 305-316 (1998). (Pubitemid 128379271)
10. Di Como, C. J. et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8, 494-501 (2002). (Pubitemid 34193969)
11. Vilgelm, A., El-Rifai, W. & Zaika, A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist. Updat. 11, 152-163 (2008).
12. Nakanishi, K., Kawai, T. & Torikata, C. Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum. Pathol. 27, 1336-1340 (1996). (Pubitemid 26415329)
13. Bringuier, P. P. et al. Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes Int. J. Cancer 79, 531-536 (1998).
14. Rey, A., Lara, P. C., Redondo, E., Valdés, E. & Apolinario, R. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer 79, 2178-2185 (1997). (Pubitemid 27227383)
15. Furihata, M. et al. Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter. Br. J. Cancer 77, 783-788 (1998). (Pubitemid 28077467)
16. Scarpini, S. et al. Impact of the expression of Aurora-A, p53, and Miβ-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol. Oncol. doi:10.1016/j.urolonc.2009.12.003.
17. Nakanishi, K. et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch. 441, 559-563 (2002). (Pubitemid 35435825)
18. Nakanishi, K. et al. Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract. Virchows Arch. 432, 445-450 (1998). (Pubitemid 28266201)
19. Fromont, G. et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur. Urol. 48, 764-770 (2005). (Pubitemid 41495375)
20. Kamijima, S. et al. The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. Int. J. Urol. 12, 941-947 (2005). (Pubitemid 43110228)
21. Keeley, F. X. Jr, Bibbo, M., McCue, P. A. & Bagley, D. H. Use of p53 in the diagnosis of upper-tract transitional cell carcinoma. Urology 49, 181-186 (1997). (Pubitemid 27074180)
22. Malats, N. et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 6, 678-686 (2005). (Pubitemid 41222758)
23. Furihata, M. et al. p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions. Int. J. Cancer 64, 298-303 (1995).
24. Furihata, M. et al. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J. Pathol. 178, 133-139 (1996). (Pubitemid 26057964)
25. Kuwahara, M., Fujisaki, N., Kagawa, S., Furihata, M. & Ohtsuki, Y. Determination of p53 protein and high-risk human papillomavirus DNA in carcinomas of the renal pelvis and ureter. Int. J. Mol. Med. 1, 703-707 (1998).
26. Cordon-Cardo, C. et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer 56, 347-353 (1994).
27. Gao, J. P. et al. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int. J. Oncol. 16, 469-475 (2000).
28. Esrig, D. et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol. 143, 1389-1397 (1993). (Pubitemid 24057109)
29. Bernardini, S. et al. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J. Urol. 162, 1496-1501 (1999). (Pubitemid 29428625)
30. Erill, N. et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn. Mol. Pathol. 13, 217-223 (2004). (Pubitemid 39552243)
31. Terrell, R. B., Cheville, J. C., See, W. A. & Cohen, M. B. Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis. J. Urol. 154, 1342-1347 (1995).
32. Yu, C. H. An overview of remedial tools for the violation of parametric test assumptions in the SAS system. In Proc. Western Users of SAS Software Conference 172-178 (2002).
33. Barros, A. J. & Hirakata, V. N. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med. Res. Methodol. 3, 21-34 (2003).
34. Nakanishi, K. et al. Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract. Virchows Arch. 432, 445-450 (1998). (Pubitemid 28266201)
35. Nakanishi, K. et al. Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract. Cancer 86, 2109-2116 (1999).
36. Nakanishi, K. et al. Expression of p27(Kip1) protein in transitional cell carcinoma of the upper urinary tract. Mod. Pathol. 14, 371-376 (2001). (Pubitemid 32448732)
37. Nakanishi, K. et al. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin. Cancer Res. 11, 2583-2590 (2005). (Pubitemid 40569457)
38. Keegan, P. E., Matthews, J. N., Lunec, J. & Neal, D. E. Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int. 85, 392-397 (2000). (Pubitemid 30142609)
39. Margulis, V. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115, 1224-1233 (2009).
40. Remzi, M. et al. Tumor architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 103, 307-311 (2009).
41. Minimo, C., Tawfiek, E. R., Bagley, D. H., McCue, P. A. & Bibbo, M. Grading of upper urinary tract transitional cell carcinoma by computed DNA content and p53 expression. Urology 50, 869-874 (1997). (Pubitemid 28021103)
42. Jinza, S., Takano, Y., Iki, M., Noguchi, S. & Masuda, M. Prognostic significance of p53 protein overexpression in transitional cell carcinoma of the renal pelvis and ureter. Urol. Int. 60, 147-151 (1998). (Pubitemid 28282418)
43. Watanabe, J. et al. Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors. J. Urol. 174, 73-75 (2005). (Pubitemid 40825675)
44. Hashimoto, H., Sue, Y., Saga, Y., Tokumitsu, M. & Yachiku, S. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int. J. Urol. 7, 457-463 (2000). (Pubitemid 32108394)
45. Zigeuner, R. et al. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63, 1079-1083 (2004). (Pubitemid 38746807)
46. Jeong, I. G. et al. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum. Pathol. 40, 668-677 (2009).